Demographic and baseline characteristics of the patients
| Patient Characteristics | ALL patients(Number (percent)) |
|---|---|
| Total no. of patients | 30 (100) |
| Median age, years (range) | 55 (26–74) |
| Sex | |
| Female | 8 (27) |
| Male | 22 (73) |
| Metastatic stage (n) | |
| M0 | 1 (3) |
| M1a | 6 (20) |
| M1b | 6 (20) |
| M1c | 17 (57) |
| Lactate dehydrogenase | |
| ≤ ULNa | 20 (67) |
| > ULN | 10 (33) |
| ECOG | |
| 0 | 19 (63) |
| 1 | 11 (37) |
| Primary site | |
| Cutaneous | 24 (80) |
| Mucosal | 2 (7) |
| Ocular | 3 (10) |
| Unknown primary | 1 (3) |
| BRAF status | |
| BRAF mutated (V600E) | 9 (30) |
| BRAF wild type | 21 (70) |
| Prior therapies** | |
| Prior adjuvant therapy | 5 (17) |
| Prior therapy with a BRAF inhibitor | 6 (20) |
| Brain metastases | |
| Patients without brain metastases | 26 (87) |
| Patients with brain metastases | 4 (13) |
aULN denotes upper limit of the normal, ** One patient (3%) received 2 weeks a of Temozolomide